These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27570417)

  • 1. New advances in targeted gastric cancer treatment.
    Lazăr DC; Tăban S; Cornianu M; Faur A; Goldiş A
    World J Gastroenterol; 2016 Aug; 22(30):6776-99. PubMed ID: 27570417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted agents for gastric and gastroesophageal junction cancer.
    Oshima T; Masuda M
    Surg Today; 2012 Apr; 42(4):313-27. PubMed ID: 22127535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
    Young K; Chau I
    Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
    Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.
    Forde PM; Kelly RJ
    Oncologist; 2013; 18(7):823-32. PubMed ID: 23853247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted therapies in advanced gastric cancer.
    Janjigian YY; Shah MA
    Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for gastric cancer: Current status and future directions (Review).
    Yuan DD; Zhu ZX; Zhang X; Liu J
    Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
    Cheung DY; Kim JK
    Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II clinical trials for gastric cancer.
    Khushalani NI
    Surg Oncol Clin N Am; 2012 Jan; 21(1):113-28. PubMed ID: 22098835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel pharmaceutical treatment approaches for gastric cancer].
    Lordick F
    Pathologe; 2017 Mar; 38(2):87-92. PubMed ID: 28220199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for gastric cancer.
    Smyth EC; Cunningham D
    Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Met targeting in advanced gastric cancer: An open challenge.
    Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
    Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line chemotherapy for patients with advanced gastric cancer.
    Takahari D
    Gastric Cancer; 2017 May; 20(3):395-406. PubMed ID: 28260227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
    Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.
    Kim HK; Green JE
    Pharmacogenomics; 2014 Feb; 15(3):375-84. PubMed ID: 24533716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
    Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
    Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
    Koustas E; Karamouzis MV; Sarantis P; Schizas D; Papavassiliou AG
    J Cell Mol Med; 2020 Sep; 24(18):10420-10431. PubMed ID: 32686903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
    Wong H; Yau T
    Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.
    Riquelme I; Saavedra K; Espinoza JA; Weber H; García P; Nervi B; Garrido M; Corvalán AH; Roa JC; Bizama C
    Oncotarget; 2015 Sep; 6(28):24750-79. PubMed ID: 26267324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.